Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome

Quilici, S; Abrams, Keith R.; Nicolas, Alain; Romero‐Martín, Macarena; Petit, Claude; Lleu, Pierre-Louis; Finnern, Henrik W.

doi:10.1016/j.sleep.2007.11.020

Cited by 51 publications

(31 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among patients with moderate-to-severe RLS (IRLS score, Ն15), a switch to SDHD resulted in an impressive IRLS score improvement of 8 to 9 points, exceeding the 6-point improvement observed in clinical trials examining the efficacy of RLS-related medications (22). In addition, after adjustment for the presence of RLS at baseline and the use of several psychotropic drugs, SDHD remained associated with a significant improvement in the majority of the sleep survey scales.…”

Section: Discussionmentioning

confidence: 91%

“…Nine of the 10 items investigate two dimensions of RLS severity, symptoms (six items), and symptoms effect (three items). This self-administered instrument was developed and validated by the IRLS Study Group (18,20) and has been used to test the efficacy of drugs developed for treatment of RLS (21,22). Responses are graded from 0 to 4, with a higher score reflecting higher severity.…”

Section: Assessment Of Rls and Symptoms Severitymentioning

confidence: 99%

“…A minimum sample size of 43 was calculated on the basis of a mean IRLS global score improvement of 6 Ϯ 9 (SD) units. This hypothesized mean score change was on the basis of pooled estimates observed in trials examining efficacy of pramipexole in the treatment of RLS compared with placebo (22).…”

Section: Sample Size Calculationmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Short Daily Hemodialysis on Restless Legs Symptoms and Sleep Disturbances

Jaber

Schiller

Burkart

et al. 2011

Clinical Journal of the American Society of Nephrology

101

View full text Add to dashboard Cite

SummaryBackground and objectives Restless legs syndrome (RLS) and sleep disturbances are common among in-center hemodialysis patients and are associated with increased morbidity/mortality. Design, setting, participants, & measurementsThe FREEDOM study is an ongoing prospective cohort study investigating the benefits of home short daily hemodialysis (SDHD) (6 times/week). In this interim report, we examine the long-term effect of SDHD on the prevalence and severity of RLS, as measured by the International Restless Legs Syndrome (IRLS) Study Group rating scale, and sleep disturbances, as measured by the Medical Outcomes Study sleep survey.Results 235 participants were included in this report (intention-to-treat cohort), of which 127 completed the 12-month follow-up (per-protocol cohort). Mean age was 52 years, 55% had an arteriovenous fistula, and 40% suffered from RLS. In the per-protocol analysis, among patients with RLS, the mean IRLS score improved significantly at month 12, after adjustment for use of RLS-related medications (18 versus 11). Among patients with moderate-to-severe RLS (IRLS score Ն15), there was an even greater improvement in the IRLS score (23 versus 13). The intention-to-treat analysis yielded similar results. Over 12 months, there was decline in the percentage of patients reporting RLS (35% versus 26%) and those reporting moderate-to-severe RLS (59% versus 43%). There was a similar and sustained 12-month improvement in several scales of the sleep survey, after adjustment for presence of RLS and use of anxiolytics and hypnotics.Conclusions Home SDHD is associated with long-term improvement in the prevalence and severity of RLS and sleep disturbances.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Assessment Of Rls and Symptoms Severitymentioning

confidence: 99%

See 1 more Smart Citation

Impact of Short Daily Hemodialysis on Restless Legs Symptoms and Sleep Disturbances

Jaber

Schiller

Burkart

et al. 2011

Clinical Journal of the American Society of Nephrology

101

View full text Add to dashboard Cite

show abstract

“…Quilici et al performed a meta-analysis of the literature to compare the efficacy and tolerability of PRA to ropinirole in RLS. 79 The analysis confirmed the significant efficacy for both drugs compared to placebo. Nausea, vomiting, dizziness, and somnolence were significantly higher for ropinirole than PRA, which also showed a superior reduction in the mean IRLS score, and a higher CGI-I response rate.…”

mentioning

confidence: 62%

Pharmacotherapy of Restless Legs Syndrome with Pramipexole

Manconi

Ferini‐Strambi

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Abstract:The dopamine agonist pramipexole (PRA) ((S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino) benzothiazole dihydrochloride; molecular formula C 10 H 17 N 3 S⋅2(HCl), is a D 3 selective compound, approved in 1997 for the treatment of Parkinson disease and in 2006 for that of idiopathic restless legs syndrome (RLS). Because of its tolerability, safety and half-life, PRA is favored over levodopa and on the other ergot derivate dopamine agonists, and it is considered nowadays one of the first choices in the therapy of RLS. PRA is rapidly and completely absorbed after oral administration, its protein binding is around 15%, it is almost unaffected by hepatic metabolism and excreted by urine unchanged. PRA has a linear pharmacokinetics, with a half-life ranging between 8 and 14 hours. Double-blind, placebo-controlled studies demonstrated that PRA, even at low dosages and since the first nights of administration, is significantly effective on the typical sensitive symptoms of RLS, on the periodic leg movements during sleep, and in improving the quality of life of patients with RLS. A subjective improvement of sleep quality is usually also reported by the patients, but the polysomnographic assessment gave less solid results on objective sleep parameters. The most common PRA related side effects include headache, nausea and orthostatic hypotension. Data on the long-term therapy of PRA in RLS, and on the efficacy of PRA in symptomatic forms of RLS are warranted to better delineate the role of PRA in RLS treatment.

show abstract

“…Des posologies supérieures entraînent habituellement l'apparition d'effets indésirables, mais la posologie peut être portée pour certains patients jusqu'à 4 mg/jour. Il n'y a pas à l'heure actuelle d'études comparatives directes entre les deux agonistes, une méta-analyse récente semble favoriser le pramipexole en termes d'efficacité et de tolérance [18]. Un patient dont les symptômes ne sont plus bien contrôlés avec un agoniste dopaminergique peut bénéficier d'un traitement par un autre agoniste.…”

Section: Encadréunclassified

Prise en charge d’un malade atteint du syndrome des jambes sans repos

Haba‐Rubio

Krieger

2010

La Presse Médicale

View full text Add to dashboard Cite

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome

Cited by 51 publications

References 40 publications

Impact of Short Daily Hemodialysis on Restless Legs Symptoms and Sleep Disturbances

Impact of Short Daily Hemodialysis on Restless Legs Symptoms and Sleep Disturbances

Pharmacotherapy of Restless Legs Syndrome with Pramipexole

Prise en charge d’un malade atteint du syndrome des jambes sans repos

Contact Info

Product

Resources

About